Table 83Study characteristics for placebo-controlled trials of omega-3 fatty acids

Omega-3 fatty acid
No. trials (Total participants)2 RCT (79)
Study IDsHALLAHAN2007
ZANARINI2003
N/% female
  1. 49/65
  2. 30/100
Mean age (or range if not given)
  1. 30
  2. 26
Axis I/II disorders
  1. 82% borderline personality disorder; severe depression at baseline (not diagnosed as major depressive disorder); recurrent self-harm
Additional intervention
  1. 53% on psychotropic medication
  2. None
Setting
  1. A&E presentations following self-harm
  2. Community
Length of treatment8 weeks
Length of follow-upNone

From: 6, PHARMACOLOGICAL AND OTHER PHYSICAL TREATMENTS IN THE MANAGEMENT OF BORDERLINE PERSONALITY DISORDER

Cover of Borderline Personality Disorder
Borderline Personality Disorder: Treatment and Management.
NICE Clinical Guidelines, No. 78.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009.
Copyright © 2009, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.